Medical Oncologist
CION Cancer Clinics
Liquid biopsy and circulating tumour DNA in liver cancer | CION Cancer Clinics
A liquid biopsy looks for tumour DNA in an ordinary blood sample. In liver cancer it is mostly a research tool today, with one practical use: finding a treatable gene change in bile duct cancer when there is not enough tissue. This page explains what the test can show, what it misses, and why it does not replace your scans, AFP or biopsy. At CION Cancer Clinics, a multidisciplinary tumour board weighs your liver function and your scans before recommending any treatment.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Can a blood test find or track liver cancer DNA?
- What could a liquid biopsy be used for in liver cancer?
- What happens if your oncologist asks for one
- The words on a liquid biopsy report, in plain language
- What families hope a blood test can do, and what it can
- Who this test does not suit, and what this page cannot tell you
- Common questions about liquid biopsy in liver cancer
The short answer
Can a blood test find or track liver cancer DNA?
Sometimes, and mostly in research. A liquid biopsy is a blood test that looks for tiny pieces of DNA shed by a tumour into the bloodstream. In liver cancer it does not yet replace scans, AFP or a tissue biopsy, and no major guideline uses it to diagnose or watch hepatocellular carcinoma (HCC) in routine care.
Which liver cancer this page is about
This page is about cancer that starts in the liver: HCC, the common kind that grows from liver cells, and intrahepatic cholangiocarcinoma, a cancer of the small bile ducts inside the liver. If your report says the cancer spread to the liver from somewhere else, such as the bowel, read what secondary liver cancer means first. Blood DNA tests are used differently there.
Where it is genuinely useful today
The clearest use is in bile duct cancer. When there is too little tissue from the biopsy to test, a blood sample can sometimes find a gene change that opens a targeted treatment. In HCC, the test is still being studied as a way to spot cancer earlier or to see whether treatment is working.
A normal liquid biopsy result does not rule out cancer. Keep every scan you have been booked for.Four possible uses
What could a liquid biopsy be used for in liver cancer?
Each use sits at a different stage of proof. Only the first is part of ordinary care, and only for some patients.
Finding a treatable gene change
In cholangiocarcinoma, the tumour's DNA can carry changes such as FGFR2 fusions or IDH1 mutations, which some targeted medicines act on. Tissue is the preferred sample. Blood is a backup when tissue runs out.
Blood can miss some changes, fusions especially, that tissue would find.Spotting cancer earlier
Researchers are testing whether blood DNA signals can pick up HCC in people with cirrhosis or hepatitis B sooner than ultrasound and AFP. This is not proven. It is not a reason to stop your regular surveillance scans.
Checking whether treatment is working
A falling level of tumour DNA may reflect a tumour that is shrinking. Studies are asking whether this tells doctors anything a scan and AFP do not. For now, decisions are still made on scans.
Looking for left-behind cancer
After surgery or ablation, some trials test whether traces of tumour DNA predict a return of the cancer. The idea is promising. It has not yet been shown to change what doctors should do.
Not sure whether this applies to you?
Ask an oncologistFrom sample to decision
What happens if your oncologist asks for one
A reason is agreed first
The test is ordered to answer one question, usually whether a bile duct cancer carries a change a medicine can target. If nobody can say what a result would change, the test is usually not worth doing.
An ordinary blood draw
Blood is taken from a vein in the arm, like any routine test. No fasting is needed for most panels. CION arranges the sample through a diagnostic partner laboratory.
The laboratory reads the DNA
The laboratory separates the fluid part of the blood and reads the free-floating DNA, searching for the gene changes on its panel. The report lists what was found and how much of it.
The tumour board reads the result
The liver tumour board weighs the report alongside your scans, liver function and biopsy. A finding becomes useful only if a medicine for it exists, suits your liver and can be obtained in India.
On your report
The words on a liquid biopsy report, in plain language
- cfDNA
- Cell-free DNA. Loose pieces of DNA in the blood, mostly from healthy cells that have died naturally.
- ctDNA
- Circulating tumour DNA. The small share of that loose DNA that came from the cancer itself.
- Not detected
- The test found no tumour DNA on its panel. The tumour may simply not be shedding enough to be seen. It is not a clear result.
- Variant allele frequency
- How much of a particular change was found compared with normal DNA. A rough measure of how much tumour DNA is in the sample.
- Panel
- The fixed list of genes the laboratory checks. A change in a gene not on the panel cannot be reported.
- Clonal haematopoiesis
- Harmless gene changes in ageing blood cells that can show up on the report and be mistaken for tumour DNA.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
What families hope a blood test can do, and what it can
"A blood test can replace the liver biopsy."
Not yet. A biopsy shows what the tumour is under the microscope. Blood DNA cannot tell HCC from cholangiocarcinoma reliably, and it can miss changes that tissue would show. Read when a liver biopsy is necessary.
"If the blood test is clear, the cancer is gone."
A test that finds nothing may mean the tumour is not shedding DNA. Your follow-up scans and AFP checks still stand, on the timetable your team gave you.
"Every finding means there is a medicine for it."
Many reported changes have no matching treatment. Some have a medicine abroad that is not approved in India, or is reachable only through a trial or import. A finding is information, not a promise.
"A positive result means it runs in the family."
Almost everything a liquid biopsy reports is in the tumour only, not inherited. Occasionally a change hints at an inherited fault, and then a separate genetic test is offered.
Being straight with you
Who this test does not suit, and what this page cannot tell you
A liquid biopsy rarely helps someone with a small HCC found on surveillance and planned for surgery, ablation or a transplant assessment. Treatment there is decided by the scan, the liver function and fitness. It is also not a screening test for a healthy person with fatty liver or hepatitis B. If a laboratory offers you one for that, ask your hepatologist first.
It cannot read your own report
The same gene name can matter a great deal or not at all, depending on the exact change and the cancer type. Bring the report to your oncologist rather than searching each gene online.
It cannot tell you about a trial near you
Much of this work happens in research. If you are curious about studies, read how to find liver cancer trials in India and ask your team whether any genuinely fits you. Nobody should feel pressed to join one.
Not sure whether a test is worth the cost? Call the helpline and ask for the case to be reviewed by the tumour board.Questions we are asked
Common questions about liquid biopsy in liver cancer
Is a liquid biopsy the same as a liver biopsy?
No. A liver biopsy takes a thin core of tissue from the tumour with a needle. A liquid biopsy is a blood draw that looks for DNA the tumour has shed. The tissue sample tells doctors far more, which is why blood is usually the backup and not the first choice.
Can a liquid biopsy diagnose liver cancer?
Not on its own. HCC is diagnosed from a contrast CT or MRI in a liver at risk, or from a biopsy when the scan is unclear. A blood DNA result can add a clue, but no guideline lets it confirm or rule out liver cancer by itself.
Can it replace my surveillance ultrasound and AFP?
No. If you have cirrhosis or hepatitis B and are on a surveillance programme, keep every ultrasound and AFP test. Blood DNA screening for liver cancer is still being studied. It has not been shown to find cancer earlier in a way that helps people.
Why would my bile duct cancer need this test?
Some bile duct cancers carry changes that a targeted medicine can act on. Tissue testing comes first. If the biopsy was too small, a blood test is a way to look without a second needle. Read why every biliary cancer should be tested.
How much does a liquid biopsy cost?
It varies by laboratory and by how many genes the panel covers, and it is quoted separately. Insurance may or may not cover it, and schemes often do not. Ask for a written estimate, and ask what decision the result will change before you pay for it.
What if my result says nothing was detected?
It means the panel found no tumour DNA in that sample. The cancer may simply not be shedding enough to be seen. Your oncologist may suggest testing tissue instead. Do not read a clear blood result as proof that there is no cancer.
Can it tell how long someone has?
No. Researchers study whether tumour DNA levels relate to how a cancer behaves, but no result should be read as a forecast for one person. Questions about the outlook belong in a conversation with your oncologist, who knows the whole picture.
Does CION do liquid biopsy?
CION oncologists decide whether a test is worth doing, arrange the sample through a diagnostic partner laboratory and review the result at the tumour board. If you already have a report from elsewhere, bring it to a consultation and it will be read with your scans.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- Cancer Research UK — Research and clinical trials for liver cancer
- National Cancer Institute — Tumor Markers
- American Cancer Society — Bile Duct Cancer Targeted Therapy
- EASL — EASL Clinical Practice Guidelines: management of hepatocellular carcinoma
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Molecular profiling in liver cancer: useful yet?The tissue version of the same questionWhy every biliary cancer should be molecularly testedWhere gene testing changes treatment todayClinical trials for liver cancer: what they areWhere most liquid biopsy work is happeningAFP and DCP: the other liver markersThe blood markers already used in practice
Talk to us
Has someone suggested a liquid biopsy?
Send us the report or the reason it was suggested, and an oncologist will tell you plainly whether the result would change the plan. One helpline serves every CION centre.